Business Context and Reporting Period
Company: Intercure Ltd. (INCR)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: Intercure is an Israeli public corporation engaged in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products. The company operates two main production facilities in Israel (Northern and Southern) and a chain of medical cannabis pharmacies. The reporting period was significantly impacted by the "Iron Swords" war following the October 7, 2023 attacks, which caused devastating damage to the Southern Facility in Nir Oz, leading to production disruptions and supply chain challenges.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (NIS '000s) | 2023 (NIS '000s) |
|---|---|---|
| Revenue | 238,845 | 355,553 |
| Gross Profit | 30,233 | 105,095 |
| Gross Margin | 12.7% | 29.6% |
| Operating Loss | (67,208) | (41,567) |
| Net Loss | (72,793) | (63,533) |
| Adjusted EBITDA | 17,962 | 53,392 |
| Cash from Operations | (66,926) | (53,631) |
| Cash & Equivalents (End of Period) | 78,318 | 101,139 |
| Total Debt (Current + Non-Current) | 183,414 | 170,396 |
Note: All figures are in thousands of New Israeli Shekels (NIS). The filing does not provide a clear USD conversion rate for the full year summary, though specific financing transactions reference approximate USD values.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 33% to NIS 238.8 million, primarily due to the destruction of the Southern Facility and subsequent production halts caused by the war.
- Margin Compression: Gross profit margin dropped from 30% in 2023 to approximately 13% in 2024. This was driven by lower revenues, a NIS 16 million inventory impairment, and market pricing pressures.
- Increased Losses: Net loss widened to NIS 72.8 million from NIS 63.5 million. While 2023 included a NIS 63 million goodwill impairment, 2024 losses were driven by operational disruptions and increased provisions for doubtful debts (NIS 16.9 million) related to the war's impact on customers.
- Government Compensation: The company received NIS 82 million in advance payments from Israeli authorities for war damages to the Southern Facility. This is recorded as other income or cost of revenue depending on the nature of the damage.
- Financing Activity: The company secured NIS 66 million in financing (including a NIS 30 million bank loan and a private placement) to support war recovery and operations, increasing total debt levels.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Recovery Plan: The Southern Facility is undergoing restoration. The company aims to triple its capacity upon full recovery, positioning it as one of the world's largest medical cannabis sites.
- Expansion: Strategic partnerships (e.g., with Cookies, Tilray, Organigram) are being leveraged for international expansion, particularly in Germany, the UK, and Austria, though regulatory hurdles and war-related delays persist.
- Pharmacy Growth: The company continues to expand its pharmacy chain (Cannolam, Leon Pharm) to diversify revenue streams.
Key Risks & Contingencies:
- Geopolitical Instability: Ongoing conflict in the Middle East poses risks to operations, supply chains, and personnel availability (military reserve call-ups).
- Regulatory Uncertainty: Delays in regulatory approvals for exports and imports (e.g., anti-dumping duties on Canadian imports) and the status of CBD delisting in Israel.
- Liquidity: Continued negative operating cash flow requires external financing to fund recovery and operations.
- Legal Proceedings: The company is involved in several lawsuits, including a class action regarding advertising (dismissed at the preliminary stage but under appeal) and disputes with former partners (Cann Pharmaceutical, Geffen Residence).
Investor Verification Checklist
- War Compensation Status: Verify the timeline and total amount of compensation expected from Israeli authorities for the Southern Facility damages beyond the NIS 82 million already received.
- Southern Facility Timeline: Confirm the specific date for the full resumption of commercial production at the Southern Facility and the associated capital expenditure requirements.
- Debt Covenants: Review the terms of the new NIS 30 million bank loan and other debt instruments to ensure compliance with financial covenants given the current loss position.
- Inventory Valuation: Assess the adequacy of the NIS 16 million inventory impairment and the net realizable value of remaining inventory given market price fluctuations.
- Regulatory Approvals: Monitor the status of export permits and the resolution of the anti-dumping duty investigation regarding Canadian imports.